Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815192 | 0.81 | CYP3A4 (0.38) | HSD11B1IDH1IDH2 | |
| SCHEMBL14833380 | 0.78 | HSD11B1 (0.45) | HSD11B1SYKIDH1HDAC8IDH2 | |
| SCHEMBL14814985 | 0.78 | HSD11B1 (0.45) | HSD11B1SYKIDH1HDAC8IDH2 | |
| SCHEMBL12526259 | 0.77 | IDH2 (0.50) | ADRB1SYKIDH1HDAC8IDH2 | |
| SCHEMBL14815283 | 0.77 | PHGDH (0.40) | HSD11B1SYKIDH1HTR2CHTR2A | |
| SCHEMBL14815203 | 0.74 | CCR6 (0.41) | HSD11B1 | |
| SCHEMBL2243533 | 0.74 | MAPK1 (0.55) | ADRB1SYKIDH1HDAC8IDH2 | |
| SCHEMBL14815130 | 0.74 | DRD2 (0.42) | HSD11B1SYKIDH1HDAC8IDH2 | |
| Hydrochloric Acid SCHEMBL3775270 | 0.73 | MAPK1 (0.53) | ADRB1SYKIDH1HDAC8IDH2 | |
| SCHEMBL30775331 | 0.72 | IDH1 (0.57) | SYKIDH1HDAC8IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | ADRB1 116/4885HSD11B1 2566/4885SYK 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.